Beyond Sterile

The Quiet Complexity of Non-Sterile Outsourcing

Chintan Shah, Director of Pharmaceutical Business Development, Vantage Specialty Chemicals

Non-sterile formulation oral solids, liquids, semi-solids, and topicals are often regarded as the mature, commoditized segment of pharmaceutical manufacturing. This article argues the opposite: it is quietly becoming more difficult. A rising proportion of new small molecules are poorly water-soluble, demanding specialized enabling technologies such as spray drying and hot-melt extrusion that relatively few contract manufacturers can offer at depth. At the same time, demand is shifting toward smaller batches, complex release profiles, high-potency oral compounds, and patient-specific products that legacy high-volume infrastructure was never designed to handle. Drawing a deliberate parallel with the sterile outsourcing bottleneck, the piece examines the analytical, scale-up, and talent pressures reshaping non-sterile development and outlines what pharmaceutical companies should look for when selecting a partner capable of solving their hardest formulation problems.

Discussions about pressure points in pharmaceutical manufacturing tend to move quickly to sterile injectables—the fill-finish bottlenecks, the growth of biologics, and the competition for capacity. A quieter development is unfolding alongside them, and it merits similar attention. Non-sterile formulation covers the oral solids, liquids, creams, gels, and topical products that make up most of the medicines patients take. This part of the industry is often regarded as mature and settled: commoditized, low-risk, and largely solved. That view no longer holds. In several respects, non-sterile work is becoming harder, not easier. A harder class of molecule The molecules emerging...

Non-sterile formulation covers the oral solids, liquids, creams, gels, and topical products that make up most of the medicines patients take. This part of the industry is often regarded as mature and settled: commoditized, low-risk, and largely solved. That view no longer holds. In several respects, non-sterile work is becoming harder, not easier.

A harder class of molecule

The molecules emerging from discovery today are more difficult to work with than those of a generation ago. A large and rising share of new small-molecule drugs dissolve poorly in water, which means the body may absorb very little of them even when the underlying chemistry is promising. Turning such a molecule into a usable medicine has become one of the central tasks of formulation.

Solving it demands specialized capability. Enabling technologies, the methods used to make a difficult molecule absorbable sit at the center of this work. Relatively few contract organizations hold both the formulation expertise and the equipment to apply them well, so the capability many modern drugs depend upon is in short supply. The effect mirrors the fill-finish bottleneck seen on the sterile side, yet attracts far less notice.

Technology	Problem it addresses
Spray drying	Creates an amorphous solid dispersion—a non-crystalline form that dissolves more readily—improving absorption of poorly soluble molecules.
Hot-melt extrusion	Disperses a drug within a carrier material to raise its solubility and the amount the body can absorb.
Particle-size reduction	Reduces particles to a fine grade (micronization), increasing the dissolution rate of low-solubility compounds.
Lipid-based systems	Carry a poorly water-soluble molecule in a fat-based vehicle to improve uptake.

Legacy infrastructure, new demands

Much oral-dose infrastructure was built for a different era of high-volume, straightforward tablets and capsules. The demand profile has since shifted. More products now arrive in small batches, with complex release profiles, patient-specific requirements, or high-potency compounds that need containment even outside a sterile environment. Oral oncology drugs, pediatric formulations, and orphan therapies for small populations all illustrate the trend. The high-volume model is poorly suited to this kind of work.

Rising analytical demands

Analytical testing has grown more complex in parallel. A poorly soluble drug reformulated as an amorphous solid dispersion, a non-crystalline form designed to dissolve more easily is not stable by default. Over time, it can revert towards its crystalline state, quietly undermining the absorption the formulation was created to deliver. Demonstrating that a product dissolves correctly and remains stable on the shelf calls for sophisticated method development and genuine analytical depth. When analytical readiness lags in early development, every later stage slows.

The value of a single site

Keeping development and manufacturing under one roof offers a clear advantage. Every transfer between sites introduces new teams, agreements and processes, and a formulation that performs well at laboratory scale often behaves differently at commercial scale. Where the same personnel carry a product from early development through scale-up, such problems surface earlier and are resolved faster.

People remain central

Beneath the equipment and facilities, expertise decides outcomes. Formulators who understand enabling technologies and who can make a difficult molecule manufacturable remain scarce. Investment in that expertise separates a partner able to solve the hardest problems from one suited only to the simplest.

From supplier to strategic partner

The shift already underway in sterile manufacturing applies here too. Non-sterile contract organizations were long regarded as venues for routine work—reliable, but interchangeable. The organizations worth partnering with now offer more, acting as strategic problem-solvers rather than suppliers of capacity alone. For a company selecting a partner, that means looking past headline capacity to a fuller set of criteria.

Choosing a non-sterile partner: Six questions

1. Depth in enabling technologies such as spray drying and hot-melt extrusion, rather than conventional tableting alone.
2. The ability to handle small, complex or high-potency batches as routine work, not as an exception.
3. Integration of development and manufacturing, so that scale-up does not begin from scratch.
4. Analytical capability strong enough to characterize difficult formulations early in development.
5. Skilled, stable formulation talent able to see a demanding program through to completion.
6. A facility designed for flexibility across multiple products.

A head start for the prepared

Non-sterile formulation is not the simple, settled field it is often assumed to be. The molecules are harder, the batches smaller, the release profiles more demanding, and the necessary expertise genuinely scarce. The organizations that prosper will not be those with the most tablet presses, but those able to take a molecule others cannot formulate and turn it into a medicine.

Sterile outsourcing holds the spotlight. The pressure on non-sterile work is no less real, and the organizations that recognize it early will hold a meaningful advantage.

References

1. Tran P, Pyo Y-C, Kim D-H, Lee S-E, Kim J-K, Park J-S. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics. 2019;11(3):132. doi:10.3390/pharmaceutics11030132.
2. Bioavailability & solubility: the promise of novel ingredients. Drug Development & Delivery. 2025. Available at: drug-dev.com.
3. Comparative assessment of spray drying and hot melt extrusion as amorphous solid dispersion manufacturing processes. American Pharmaceutical Review. 2020. Available at: americanpharmaceuticalreview.com.
4. Amorphous solid dispersions: stability mechanism, design strategy and key production technique of hot-melt extrusion. International Journal of Pharmaceutics. 2023. Available at: sciencedirect.com (article S0378517323009110).
5. Oral solid dosage CDMO market size, share & trends analysis report, 2025-2030. Grand View Research; 2024. Available at: grandviewresearch.com.
6. Oral solid dose oncology CDMO market. Precedence Research; 2025. Available at: precedenceresearch.com.
7. Long-term physical stability of amorphous solid dispersions: comparison of detection powers of common evaluation methods for spray-dried and hot-melt extruded formulations. Journal of Pharmaceutical Sciences. 2024. Available at: jpharmsci.org.
8. Oral solid dosage (OSD) contract manufacturing market report. PharmaSource; 2025. Available at: pharmasource.global.

--PFAm Issue 08--